Evidence map›Paper›PMID 40911721›Full record

ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2025

Moderating effects of plasma glial fibrillary acidic protein along the Alzheimer's disease continuum.

Shannon Y Lee, Valentina E Diaz, Olivia M Emanuel, Emily F Matusz, Julia Webb, Brandon Chan, Argentina Lario Lago, Wei-En Wang, Jesse DeSimone, Julio C Rojas and 26 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Moderating effects of plasma glial fibrillary acidic protein along the Alzheimer's disease continuum.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

36 authors.

Shannon Y LeeDepartment of Clinical and Health Psychology, University of Florida, Gainesville, Florida, USA.ORCID 0000-0001-6820-1237
Valentina E DiazDepartment of Neurology, Memory and Aging Center, Weill Institute for Neurosciences, University of California San Francisco, San Francisco, California, USA.
Olivia M EmanuelDepartment of Clinical and Health Psychology, University of Florida, Gainesville, Florida, USA.
Emily F MatuszDepartment of Clinical and Health Psychology, University of Florida, Gainesville, Florida, USA.
Julia WebbDepartment of Neurology, Memory and Aging Center, Weill Institute for Neurosciences, University of California San Francisco, San Francisco, California, USA.
Brandon ChanDepartment of Neurology, Memory and Aging Center, Weill Institute for Neurosciences, University of California San Francisco, San Francisco, California, USA.
Argentina Lario LagoDepartment of Neurology, Memory and Aging Center, Weill Institute for Neurosciences, University of California San Francisco, San Francisco, California, USA.
Wei-En Wang1Florida Alzheimer's Disease Research Center, Gainesville, Florida, USA.
Jesse DeSimone1Florida Alzheimer's Disease Research Center, Gainesville, Florida, USA.
Julio C RojasDepartment of Neurology, Memory and Aging Center, Weill Institute for Neurosciences, University of California San Francisco, San Francisco, California, USA.
Lawren VandeVredeDepartment of Neurology, Memory and Aging Center, Weill Institute for Neurosciences, University of California San Francisco, San Francisco, California, USA.
Renaud La JoieDepartment of Neurology, Memory and Aging Center, Weill Institute for Neurosciences, University of California San Francisco, San Francisco, California, USA.
Shellie-Anne LevyDepartment of Clinical and Health Psychology, University of Florida, Gainesville, Florida, USA.
Franchesca AriasDepartment of Clinical and Health Psychology, University of Florida, Gainesville, Florida, USA.
Brenda A WiensDepartment of Clinical and Health Psychology, University of Florida, Gainesville, Florida, USA.
Idaly Velez-Uribe1Florida Alzheimer's Disease Research Center, Gainesville, Florida, USA.
Warren W Barker1Florida Alzheimer's Disease Research Center, Gainesville, Florida, USA.
Emily W PaolilloDepartment of Neurology, Memory and Aging Center, Weill Institute for Neurosciences, University of California San Francisco, San Francisco, California, USA.
Mark Sanderson-CiminoDepartment of Neurology, Memory and Aging Center, Weill Institute for Neurosciences, University of California San Francisco, San Francisco, California, USA.
Monica Rosselli1Florida Alzheimer's Disease Research Center, Gainesville, Florida, USA.
Sruti Rayaprolu1Florida Alzheimer's Disease Research Center, Gainesville, Florida, USA.
Tatjana Rundek1Florida Alzheimer's Disease Research Center, Gainesville, Florida, USA.
Rosie E Curiel Cid1Florida Alzheimer's Disease Research Center, Gainesville, Florida, USA.
David E Vaillancourt1Florida Alzheimer's Disease Research Center, Gainesville, Florida, USA.
Melissa J Armstrong1Florida Alzheimer's Disease Research Center, Gainesville, Florida, USA.
Michael MarsiskeDepartment of Clinical and Health Psychology, University of Florida, Gainesville, Florida, USA.
Steven T DeKosky1Florida Alzheimer's Disease Research Center, Gainesville, Florida, USA.
David A Loewenstein1Florida Alzheimer's Disease Research Center, Gainesville, Florida, USA.
Ranjan Duara1Florida Alzheimer's Disease Research Center, Gainesville, Florida, USA.
Glenn E SmithDepartment of Clinical and Health Psychology, University of Florida, Gainesville, Florida, USA.
Adam StaffaroniDepartment of Neurology, Memory and Aging Center, Weill Institute for Neurosciences, University of California San Francisco, San Francisco, California, USA.
Gil D RabinoviciDepartment of Neurology, Memory and Aging Center, Weill Institute for Neurosciences, University of California San Francisco, San Francisco, California, USA.
Kaitlin B CasalettoDepartment of Clinical and Health Psychology, University of Florida, Gainesville, Florida, USA.
Joel H KramerDepartment of Neurology, Memory and Aging Center, Weill Institute for Neurosciences, University of California San Francisco, San Francisco, California, USA.
Rowan SalonerDepartment of Neurology, Memory and Aging Center, Weill Institute for Neurosciences, University of California San Francisco, San Francisco, California, USA.
Breton M AskenDepartment of Clinical and Health Psychology, University of Florida, Gainesville, Florida, USA.

Funding

Research Education ComponentP30AG062422 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Jennifer S Yokoyama · 2019 to 2026
$36.9M
Social Determinants of Health, Race/Ethnicity, and White Matter HyperintensitiesP30AG066506 · NIA · UNIVERSITY OF FLORIDA · PI Ranjan Duara, DAVID LOEWENSTEIN · 2020 to 2026
$25.6M
Mechanisms of Executive Decline in Normal AgingR01AG032289 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Kaitlin B Casaletto, JOEL H KRAMER · 2009 to 2026
$8.3M
Unraveling the intersection of synaptic biology, lifestyle, and cognitive resilienceR01AG072475 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CASALETTO, KAITLIN B · 2021 to 2025
$4.3M
Effects of chronic inflammation on brain structure and functionR01AG048234 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI KRAMER, JOEL H · 2015 to 2019
$3.2M
Early Age-of-Onset AD: Clinical Heterogeneity and Network DegenerationR01AG045611 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI RABINOVICI, GIL DAN · 2014 to 2018
$3.1M
Novel Imaging and Biofluid Biomarkers of Small Vessel Cerebrovascular DiseaseUF1NS100608 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI KRAMER, JOEL H · 2021 to 2021
$2.5M
Validation of Novel Plasma Biomarkers for Mixed Etiology DementiaK23AG073514 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI VANDEVREDE, LAWREN · 2021 to 2025
$1.0M
Can Behavior Shape Neural Health? Identifying Modifiable Factors to Prevent Cognitive Decline in AgeK23AG058752 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CASALETTO, KAITLIN B · 2018 to 2022
$994k
Passive digital phenotyping for capturing real-world neurobehavior in neurodegenerative diseaseK23AG084883 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Emily Paolillo · 2024 to 2026
$592k
Deciphering the molecular landscape of frontotemporal lobar degeneration: A network-based proteomic approachK23AG090757 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Rowan Saloner · 2025 to 2026
$400k
Alzheimer's Association Research AARF-22-974065Alzheimer's Association Research AARF-23-1145318Alzheimer's Association Research AARG-20-683875Larry L. Hillblom Foundation 2018-A-006-NETLarry L. Hillblom Foundation 2024-A-001-CTRNew Vision Research Charleston Conference on Alzheimer's Disease 2024-001-1NIA) K23AG058752NIA) K23AG073514NIA) K23AG084883NIA) P30AG062422NIA) P30AG066506NIA) R01AG032289NIA) R01AG045611NIA) R01AG048234NIA) R01AG072475NIA) UF1NS100608NIA NIH HHS K23 AG058752NIA NIH HHS K23 AG073514NIA NIH HHS K23 AG084883NIA NIH HHS K23 AG090757NIA NIH HHS P30 AG062422NIA NIH HHS P30 AG066506NIA NIH HHS R01 AG032289NIA NIH HHS R01 AG045611NIA NIH HHS R01 AG048234NIA NIH HHS R01 AG072475NIH)NINDS NIH HHS UF1 NS100608
6 · The paper itself

Abstract

introductionGlial fibrillary acidic protein (GFAP) may contribute to Alzheimer's pathology at early disease stages. GFAP moderation of Alzheimer's disease (AD)-related neurodegeneration and cognition is unclear.

methodsWe examined plasma GFAP moderation of AD biomarkers (amyloid beta [Aβ]-positron emission tomography [PET][A]; plasma phosphorylated tau-181 [p-tau181][T

resultsPlasma GFAP consistently moderated A-T DISCUSSION: Across demographically and clinically heterogeneous cohorts, plasma GFAP is a key moderator of AD and may help identify individuals at greatest risk of AD-related neurodegeneration and cognitive decline. HIGHLIGHTS: AD biomarkers were measured in two demographically and clinically distinct cohorts. Plasma GFAP moderated Aβ-PET to p-tau associations in both UCSF and 1FLADRC. Cohort-dependent, GFAP moderated p-tau to neurodegeneration and cognition associations. All moderations revealed strengthened disease associations with higher plasma GFAP. Plasma GFAP may help identify individuals at greatest risk of AD-related decline.

Indexed as

Alzheimer DiseaseGlial Fibrillary Acidic ProteinAgedAged, 80 and overAmyloid beta-PeptidesBiomarkersBrainCohort StudiesFemaleHumansMagnetic Resonance ImagingMalePositron-Emission Tomographytau ProteinsAmyloid beta-PeptidesBiomarkersGFAP protein, humanGlial Fibrillary Acidic Proteintau ProteinsAlzheimer's diseaseastrocyte reactivityATNcognitionGFAPglial fibrillary acidic proteininflammationneurodegenerationneuroinflammationneuropathologyplasma biomarkersplasma GFAP

Identifiers

PMID40911721
PMCPMC12412752

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.